Novel treatment offers kidney failure patients with rare disorder new hope

May 3, 2017
A novel treatment offers kidney failure and kidney transplant patients with a rare disorder new hope. The treatment allows targeted elimination of plasma cell clones producing abnormal proteins that deposits in the kidneys and leads to kidney failure, according to new research. Credit: Intermountain Medical Center

A novel treatment offers kidney failure and kidney transplant patients with a rare disorder new hope. The treatment allows targeted elimination of plasma cell clones producing abnormal proteins that deposits in the kidneys and leads to kidney failure, according to new research.

This is the first time this new approach has been used successfully anywhere in the world for the disorder, known as Monclonal Gammopathy of Renal Significance. This finding opens the door for additional research, say the researchers from the Intermountain Medical Center Kidney Transplantation Program in Salt Lake City.

Researchers presented results of the case study during the American Transplant Congress' annual conference in Chicago this week. Their research was awarded a Poster of Distinction Award from the Congress.

In with the disorder, monoclonal in the bone marrow create an that's deposited in the and causes inflammation that impacts the organ's ability to function. If left untreated, the kidneys will eventually fail.

Unfortunately, a kidney transplant doesn't fix the problem, because the continued presence of the abnormal proteins will eventually destroy the new kidney. A compromised immune system following transplantation surgery makes the patient even more vulnerable to adverse effects, which leaves the patient with only one option: a lifetime of dialysis.

"Conventional therapies used to treat MGRS don't always work, which leaves the patient with few options," said Sanjiv Anand, MD, MS, transplant nephrologist with the Intermountain Medical Center Kidney Transplantation Program, and lead author of the study. "After trying all the conventional therapies with our patient, we decided to go one step further and move forward with an off-label use of a relatively new drug called Daratumumab."

In the case report, a 65-year-old man with end-stage renal disease was transplanted with a new kidney. Six months after the transplant, he had worsening and high levels of protein in his urine. A showed development of a subtype of MGRS- Proliferative Glomerulonephritis with Monoclonal Immune Deposits, so doctors tried using the two conventional approaches, but observed no response.

The patient was then put on Daratumumab, a medication approved last year for treating multiple myeloma, or high levels of monoclonal plasma cell populations found in bone marrow. Daratumumab targets the plasma cell clones in the that produce the abnormal protein.

"Following seven doses of Daratumumab, the patient's proteinuria numbers remarkably improved from 9.7 gm/d to only 0.7 gm/d and his renal function dramatically improved," said Dr. Anand.

"Dr. Anand's work demonstrates the efficacy of Daratumumab in the setting of PGNMID," added Titte Srinivas, MD, FAST, medical director of the Intermountain Medical Center Kidney Transplantation Program. "The ability of Daratumumab to directly target plasma cells affords a new way to treat plasma cell disorders with a positive impact on kidney function with minimal off-target effects. This novel way of impacting plasma cells allows us to specifically treat the problem and get him back to doing what he loves without having to spend hours a week in a dialysis center."

The team is now extending these observations to the treatment of antibody mediated rejection in kidney transplant and MGRS patients where current therapies are lacking in sustainable efficacy.

Explore further: New anti-rejection drug reduces weight gain and enhances outcomes for liver transplant recipients

Related Stories

New anti-rejection drug reduces weight gain and enhances outcomes for liver transplant recipients

May 2, 2017
Researchers have discovered that a new anti-rejection drug that is gentler on the kidneys after liver transplant also reduces weight gain, which is common after surgery and can lead to serious complications for transplant ...

Timing of anti-donor antibody responses affects the survival of kidney transplants

March 2, 2017
New research provides insights on transplant recipients' antibody responses against donor kidneys and how the timing of those responses can have important implications. The findings appear in an upcoming issue of the Journal ...

Prevent diabetic kidney function deterioration

February 10, 2017
Since the progress of diabetic kidney disease is difficult to slow, many patients have to undergo dialysis or kidney transplantation. However, researchers at Karolinska Institutet have managed to prevent diabetic kidney function ...

Physicians can better predict outcomes for kidney transplant patients with key data, study finds

January 6, 2017
Kidney transplant patients have a better chance of survival if physicians use all the data that's available to them—including data that's tracked over time—to predict the likelihood of organ failure, according to new ...

Case of hepatitis E transmission via plasma exchange

March 2, 2016
(HealthDay)—A case of hepatitis E virus (HEV) infection has been reported in a kidney transplant recipient, according to a research letter published online March 1 in the Annals of Internal Medicine.

Age, not post-op infection, more important for kidney transplant success, study finds

September 22, 2015
Infection by virus cytomegalovirus (CMV) is a common and major complication following kidney transplantation. Previous studies have related CMV infection with increased kidney transplant failure and reduced patient survival. ...

Recommended for you

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.